Drug Landscape ›
CETRORELIX ACETATE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 143
Most-reported reactions
Ovarian Hyperstimulation Syndrome — 20 reports (13.99%) Condition Aggravated — 19 reports (13.29%) Drug Ineffective — 19 reports (13.29%) Generalised Tonic-Clonic Seizure — 19 reports (13.29%) Drug Interaction — 18 reports (12.59%) Drug Level Decreased — 18 reports (12.59%) Blood Oestrogen Increased — 10 reports (6.99%) Abortion Spontaneous — 8 reports (5.59%) Abdominal Pain — 6 reports (4.2%) Ascites — 6 reports (4.2%)
Source database →
CETRORELIX ACETATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is CETRORELIX ACETATE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for CETRORELIX ACETATE in United States?
Marketing authorisation holder not available in our data.